Abstract
You have accessJournal of UrologyBladder Cancer: Upper Tract Tumors II1 Apr 2014MP77-17 IS THERE EVIDENCE OF DISCORDANT BIOLOGY IN UROTHELIAL CANCER OF THE LOWER AND UPPER URINARY TRACT? PROSPECTIVE COMPARISON OF MOLECULAR SIGNATURES Laura-Maria Krabbe, Yair Lotan, Aditya Bagrodia, Bishoy A. Gayed, Oussama M. Darwish, Ramy F. Youssef, Christian Bolenz, Arthur I. Sagalowsky, Ganesh V. Raj, Shahrokh F. Shariat, Payal Kapur, and Vitaly Margulis Laura-Maria KrabbeLaura-Maria Krabbe More articles by this author , Yair LotanYair Lotan More articles by this author , Aditya BagrodiaAditya Bagrodia More articles by this author , Bishoy A. GayedBishoy A. Gayed More articles by this author , Oussama M. DarwishOussama M. Darwish More articles by this author , Ramy F. YoussefRamy F. Youssef More articles by this author , Christian BolenzChristian Bolenz More articles by this author , Arthur I. SagalowskyArthur I. Sagalowsky More articles by this author , Ganesh V. RajGanesh V. Raj More articles by this author , Shahrokh F. ShariatShahrokh F. Shariat More articles by this author , Payal KapurPayal Kapur More articles by this author , and Vitaly MargulisVitaly Margulis More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.2480AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Urothelial carcinoma (UC) is a disease of the entire urothelium and may occur anywhere along the urinary tract. The vast majority of UC arises in the bladder, whereas only about 5-10% of UC occur in the Upper urinary tract. Upper tract urothelial carcinoma (UTUC) is less well studied than bladder cancer (BC) due to its rarity. It remains questionable if findings in BC can safely be extrapolated to UTUC. Therefore, we prospectively evaluate molecular profiles of UTUC and BC using a cell cycle biomarker panel. METHODS Immunohistochemical staining for p21, p27, p53, cyclin E and Ki-67 was prospectively performed on 96 UTUC and 159 BC patients with non-metastatic high-grade UC treated with extirpative surgery. Data was compared between those two groups according to the pathological stage. Primary outcome was assessment of differences in marker expression. A previously validated marker score (MS) was calculated. The marker score was considered favorable if ¡Ü2 of the above mentioned markers were altered and unfavorable if >2 markers were altered. Secondary outcome was difference in survival according to marker status. RESULTS Over a median follow up of 22.0 months, 31.2% of patients with UTUC and 28.3% of patients with BC recurred and 20.8% and 27.7% died of UTUC and BC, respectively. Number of altered markers was not significantly different between the study groups. 34 patients (35.4%) with UTUC and 62 patients (39.0%) with BC had an unfavorable marker score (MS) (>2 markers altered). There were no significant differences between UTUC and BC in alteration status of markers, number of altered markers and MS when sub-stratified by pathologic stage. There were no significant differences in survival outcomes between UTUC and BC patients, according to number of altered markers and MS (figure). CONCLUSIONS Our results demonstrate molecular similarity of UTUC and BC regarding cell cycle and proliferative tissue markers. These findings have important implications and support further extrapolation of treatment paradigms established in BC to UTUC. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e918 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Laura-Maria Krabbe More articles by this author Yair Lotan More articles by this author Aditya Bagrodia More articles by this author Bishoy A. Gayed More articles by this author Oussama M. Darwish More articles by this author Ramy F. Youssef More articles by this author Christian Bolenz More articles by this author Arthur I. Sagalowsky More articles by this author Ganesh V. Raj More articles by this author Shahrokh F. Shariat More articles by this author Payal Kapur More articles by this author Vitaly Margulis More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.